Chitosan oligosaccharide improves the therapeutic efficacy of sitagliptin for the therapy of Chinese elderly patients with type 2 diabetes mellitus
Autor: | Tingli Sun, Lina Wang, Lijie Zhao |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2017 |
Předmět: |
medicine.medical_specialty
Combination therapy Therapeutics and Clinical Risk Management type 2 diabetes mellitus 030209 endocrinology & metabolism 030204 cardiovascular system & hematology Hypoglycemia sitagliptin C-reactive protein 03 medical and health sciences 0302 clinical medicine Insulin resistance Internal medicine insulin sensitivity Medicine Pharmacology (medical) General Pharmacology Toxicology and Pharmaceutics Original Research Glycemic Chemical Health and Safety adiponectin Adiponectin business.industry General Medicine medicine.disease Glucagon-like peptide-1 glucagon-like peptide 1 Endocrinology Sitagliptin chitosan oligosaccharide Resistin business Safety Research medicine.drug |
Zdroj: | Therapeutics and Clinical Risk Management |
ISSN: | 1178-203X |
Popis: | Lijie Zhao,1 Tingli Sun,2 Lina Wang1 1Department of Geriatrics, 2Department of Nephrology, General Hospital of Daqing Oil Field, Daqing, China Abstract: Sitagliptin improves glycemic control in type 2 diabetes mellitus (T2DM) patients but its side effects are undesirable. Chitosan oligosaccharide (COS) is expected to improve the therapeutic result as a natural product. A total of 200 elderly T2DM patients were evenly assigned into four groups: sitagliptin group (SG), receiving sitagliptin 100 mg/day; COS group (CG), receiving COS 100 mg/day; combination therapy of sitagliptin and COS group (SCG), receiving both sitagliptin and COS 100 mg/day; and placebo group (PG), receiving placebo 100 mg/day. After 42-week therapy, biochemical indices and clinical parameters for the alterations from start points were analyzed. The related molecular mechanism was tested by quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot at cell level. Lower risk of hypoglycemia was found in the SCG group when compared with SG and other groups (P2.5% (P |
Databáze: | OpenAIRE |
Externí odkaz: |